ANANDA Scientific and Diabetes
The diabetes problem is enormous in its scope, with approximately 375 million patients worldwide and more than 550 million forecast by 2030. China alone now has 114 million diabetes patients and 200-300 million pre-diabetics (the medical stage immediately preceding diabetes in which blood sugar levels are abnormally high). Approximately 4 million people die each year from it. Diabetes represented at least $465 billion in global healthcare expenditures in 2011. Insulin injections are the principal way in which diabetes is maintained, but many patients remain infirm or are dying due to the inappropriateness of insulin for tactical and economical reasons. There exists an enormous unmet demand for cost-effective oral medicines able to control diabetes, and cannabinoids appear well suited in this purpose.
ANANDA Scientific has unique, intellectual property regarding cannabidiol (CBD)-based diabetes therapy and is pursuing professionally-refereed, science-based clinical work for bringing what it considers an improved and essential way to control diabetes into the medical market place. CBD may even help prevent diabetes.